Header Logo

Connection

MICHAEL LEWIS to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications MICHAEL LEWIS has written about Xenograft Model Antitumor Assays.
MICHAEL LEWIS
Connection Strength
2.247
Xenograft Model Antitumor Assays
  1. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013 Aug 01; 73(15):4885-97.
    View in: PubMed
    Score: 0.349
  2. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207.
    View in: PubMed
    Score: 0.330
  3. The Power and Promise of Patient-Derived Xenografts of Human Breast Cancer. Cold Spring Harb Perspect Med. 2024 04 01; 14(4).
    View in: PubMed
    Score: 0.185
  4. Surgical Procedure for Implantation of Human Tumor Tissue into the Epithelium-Free Mammary Fat Pad of Immunocompromised Mice to Generate Patient-Derived Xenografts (PDX). Methods Mol Biol. 2022; 2471:195-207.
    View in: PubMed
    Score: 0.158
  5. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun. 2021 08 24; 12(1):5086.
    View in: PubMed
    Score: 0.154
  6. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet. 2021 01; 53(1):86-99.
    View in: PubMed
    Score: 0.148
  7. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Res. 2017 11 01; 77(21):e62-e66.
    View in: PubMed
    Score: 0.118
  8. Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater. 2017 08; 58:466-478.
    View in: PubMed
    Score: 0.114
  9. STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. Stem Cells. 2014 Oct; 32(10):2571-82.
    View in: PubMed
    Score: 0.096
  10. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27.
    View in: PubMed
    Score: 0.074
  11. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694.
    View in: PubMed
    Score: 0.056
  12. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer. 2022 02; 3(2):232-250.
    View in: PubMed
    Score: 0.040
  13. MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade. Nat Commun. 2022 01 11; 13(1):245.
    View in: PubMed
    Score: 0.040
  14. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 12 15; 81(24):6259-6272.
    View in: PubMed
    Score: 0.039
  15. MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC. JCI Insight. 2020 08 06; 5(15).
    View in: PubMed
    Score: 0.036
  16. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Mol Cancer Res. 2019 10; 17(10):2063-2076.
    View in: PubMed
    Score: 0.033
  17. Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer Res. 2019 08 15; 79(16):4258-4270.
    View in: PubMed
    Score: 0.033
  18. C/EBPd links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes. Oncogene. 2019 05; 38(20):3765-3780.
    View in: PubMed
    Score: 0.032
  19. gpGrouper: A Peptide Grouping Algorithm for Gene-Centric Inference and Quantitation of Bottom-Up Proteomics Data. Mol Cell Proteomics. 2018 11; 17(11):2270-2283.
    View in: PubMed
    Score: 0.031
  20. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
    View in: PubMed
    Score: 0.030
  21. Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest. 2018 04 02; 128(4):1283-1299.
    View in: PubMed
    Score: 0.030
  22. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018 01 15; 78(2):489-500.
    View in: PubMed
    Score: 0.030
  23. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017 04 13; 544(7649):250-254.
    View in: PubMed
    Score: 0.028
  24. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 2015 Feb 10; 17:17.
    View in: PubMed
    Score: 0.025
  25. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res. 2013 Mar 15; 19(6):1512-24.
    View in: PubMed
    Score: 0.021
  26. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.